# Copenhagen Head Injury Ciclosporin (CHIC) Study

> **NCT01825044** · PHASE2 · COMPLETED · sponsor: **NeuroVive Pharmaceutical AB** · enrollment: 16 (actual)

## Conditions studied

- Traumatic Brain Injury

## Interventions

- **DRUG:** NeuroSTAT 5 mg/kg/day
- **DRUG:** NeuroSTAT 10 mg/kg/day

## Key facts

- **NCT ID:** NCT01825044
- **Lead sponsor:** NeuroVive Pharmaceutical AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2017-09-21
- **Final completion:** 2017-09-21
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01825044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01825044, "Copenhagen Head Injury Ciclosporin (CHIC) Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01825044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*